Original BioMedicals Co., Ltd. (TPEX:6483)
Taiwan
· Delayed Price · Currency is TWD 15.85
-0.90 (-5.37%)
At close: Mar 9, 2026
Original BioMedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.38 | - | 0.04 | 0.11 | - | - | Upgrade
|
| Revenue Growth (YoY) | 786.05% | - | -59.81% | - | - | - | Upgrade
|
| Cost of Revenue | 0.08 | - | 0.01 | 0.01 | - | - | Upgrade
|
| Gross Profit | 0.31 | - | 0.04 | 0.1 | - | - | Upgrade
|
| Selling, General & Admin | 52.83 | 45.28 | 34.59 | 17.36 | 11.92 | 11.68 | Upgrade
|
| Research & Development | 41.44 | 33.05 | 24.71 | 22.91 | 20.74 | 22.06 | Upgrade
|
| Operating Expenses | 94.27 | 78.33 | 59.3 | 40.27 | 32.67 | 33.74 | Upgrade
|
| Operating Income | -93.97 | -78.33 | -59.26 | -40.18 | -32.67 | -33.74 | Upgrade
|
| Interest Expense | -0.74 | -0.87 | -1.07 | -1.2 | -1.39 | -1.56 | Upgrade
|
| Interest & Investment Income | 3.82 | 4.19 | 0.7 | 0.47 | 0.14 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.59 | 0.01 | -0 | 0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.03 | 0.62 | 0.04 | 0.55 | Upgrade
|
| EBT Excluding Unusual Items | -90.3 | -75 | -59.66 | -40.28 | -33.88 | -34.75 | Upgrade
|
| Pretax Income | -90.3 | -75 | -59.66 | -40.28 | -33.88 | -34.75 | Upgrade
|
| Net Income | -90.3 | -75 | -59.66 | -40.28 | -33.88 | -34.75 | Upgrade
|
| Net Income to Common | -90.3 | -75 | -59.66 | -40.28 | -33.88 | -34.75 | Upgrade
|
| Shares Outstanding (Basic) | 66 | 66 | 49 | 47 | 42 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 66 | 66 | 49 | 47 | 42 | 28 | Upgrade
|
| Shares Change (YoY) | 13.19% | 33.68% | 4.87% | 13.05% | 50.66% | 15.49% | Upgrade
|
| EPS (Basic) | -1.36 | -1.14 | -1.21 | -0.86 | -0.81 | -1.26 | Upgrade
|
| EPS (Diluted) | -1.37 | -1.14 | -1.21 | -0.86 | -0.81 | -1.26 | Upgrade
|
| Free Cash Flow | -82.24 | -85.95 | -27.81 | -30.89 | -26.86 | -23.94 | Upgrade
|
| Free Cash Flow Per Share | -1.24 | -1.30 | -0.56 | -0.66 | -0.65 | -0.87 | Upgrade
|
| Gross Margin | 80.31% | - | 81.39% | 88.78% | - | - | Upgrade
|
| Operating Margin | -24662.73% | - | -137818.61% | -37547.66% | - | - | Upgrade
|
| Profit Margin | -23699.74% | - | -138746.51% | -37642.06% | - | - | Upgrade
|
| Free Cash Flow Margin | -21584.78% | - | -64674.42% | -28864.49% | - | - | Upgrade
|
| EBITDA | -89.42 | -74.05 | -54.64 | -35.64 | -27.43 | -25.26 | Upgrade
|
| D&A For EBITDA | 4.54 | 4.29 | 4.62 | 4.54 | 5.24 | 8.48 | Upgrade
|
| EBIT | -93.97 | -78.33 | -59.26 | -40.18 | -32.67 | -33.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.